A Phase 2 interventional study of Fuzheng Huayu Tablet and Vitamin C tablets in Pulmonary Fibrosis Due to COVID-19, sponsored by ShuGuang Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-01-03.
Sponsored by ShuGuang Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 472 studies in COVID-19 with a site in China — 53 open to participants now, 75 under way, 8 of them phase 3. COVID-19 · China.
Among the 472 studies in COVID-19 with a site in China, this one is the 187th largest by enrollment of the 330 interventional ones that give a count, is one of 123 that started in 2020, is one of 48 in phase 2, and was the 17th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →53 of the 472 studies in COVID-19 with a site in China are open now. Recruiting first, the newest first:
Pfizer · Sites in China, United States, Argentina and 16 more countries
Ages 12+
Zhongnan Hospital · Sites in China
Ages 18+ · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Sichuan Provincial People's Hospital · Sites in China
Ages 18–90
WestVac Biopharma Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
472 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 91 · Phase 3 58 · Phase 4 53
First in 2013; this study’s year is marked. 123 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 200 across the 330 interventional studies, 388 across the 142 observational. Of the 207 that completed or were terminated, 5 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
183 of 472 have an industry lead sponsor. The 10 most frequent:
ShuGuang Hospital is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
ShuGuang Hospital has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
3 of the studies in COVID-19 with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07678619Peking UniversitySmart Analysis and Decision-Making for Emerging Infectious Diseases | 2027-07-17 |
Add all 3 to your calendar (.ics) → With an account.
Among the 472 studies in COVID-19 with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
According to previous studies, viral pneumonia can develop into pulmonary fibrosis, which can affect patients'lung function and even life health.This study aims to observe the efficacy and safety of Fuzheng Huayu Tablets in the treatment of pulmonary fibrosis after COVID-19.
The patients with COVID-19 could suffered from the pulmonary dysfunction and/or fibrosis the recovery period, but there are no certain drugs or treatment to cope with this situation. Our previous studies indicated that Fuzheng Huayu tablets (FZHY) could regress the lung fibrosis induced by bleomycin in animals, and improve the pulmonary function in the patients with chronic obstructive pulmonary disease. Now we design this trial to carry out the clinical study in order to evaluate the effects of Fuzheng Huayu tablets on pulmonary fibrosis and/or pulmonary function injury in the recovery period of COVID-19 and expect to improve the prognosis.
This is a randomized, double-blind, multicenter, placebo-controlled clinical trial.It enrolls 142 patients who had been diagnosed with COVID-19, but currently they are negative for viral testing and have developed pulmonary fibrosis or pulmonary dysfunction. They are randomly assigned into Placebo group and FZHY group. All patients are given usual treatment such as respiratory function rehabilitation training and vitamin C. The FZHY group is given Fuzheng Huayu tablets, and the control group is given placebo. Each patient will be observed for 24 weeks and followed up for 8 weeks. The primary outcomes for the trial are the improvement proportion of pulmonary fibrosis judged by HRCT score and the improvement of lung function(FVC,FEV1,FVC/FEV1). Secondary outcomes include six-minute walk distance, improvement proportion of pulmonary inflammation, improvement proportion of clinical symptoms , quality of Life-BREF (QOL-BREF) Score, patient health questionnaire-9 (PHQ-9) Score, general anxiety disorder-7 (GAD-7) score. The safety also be observed.
Inclusion criteria (I) Discharged patients fulfilling the diagnostic criteria of COVID-19 (China Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7); (II) COVID-19 RNA in respiratory specimens or blood specimens of patients is negative (>2 times), assayed by real-time fluorescent polymerase chain reaction test (RT-PCR); (III) Pulmonary CT scans within 7 days showed that there were still unabsorbed inflammation or pulmonary fibrosis in the lungs; (IV) Age 18-70.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
usual treatment (respiratory function rehabilitation training + Vitamin C tablets) * Fuzheng Huayu tablets
Drug: Fuzheng Huayu Tablet · Drug: Vitamin C tablets · Other: respiratory function rehabilitation training
usual treatment (respiratory function rehabilitation training + Vitamin C tablets) * placebo
Drug: Vitamin C tablets · Drug: Placebo · Other: respiratory function rehabilitation training
FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
Also known as: FZHY
Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral;
Also known as: VC
Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
Health exercise, once a day
The improvement proportion of pulmonary fibrosis
Evaluation of pulmonary fibrosis Improvement. pulmonary fibrosis judged by HRCT score.HRCT images are divided into four grades according to the score, and a reduction of one grade is an improvement.
Time frame: Week 24
The improvement of lung function
FVC, FEV1, FVC/FEV1
Time frame: Week 24
The improvement proportion of pulmonary inflammation
Evaluation of pulmonary inflammation Improvement
Time frame: Week 24
The improvement proportion of clinical symptom
Discomfort symptoms include dyspnea, cough, exhausted, fatigue, insomnia, sweating, poor appetite, diarrhea, etc., which are common manifestations of patients with COVID-19
Time frame: Week 24
Quality of Life-BREF (QOL-BREF)
This scale can reflect the quality of life of patients to some extent.
Time frame: Week 24
Patient Health Questionnaire-9(PHQ-9)
This scale can reflect the quality of life of patients to some extent.
Time frame: Week 24
Generalized anxiety disorder-7(GAD-7)
This scale can reflect the quality of life of patients to some extent.
Time frame: Week 24
The 6-minute walk distance
Evaluation of Lung Function Improvement
Time frame: Week 24
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2020 to primary completion in Mar 2021, 11 months.
Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 11 months is close to that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fuzheng huayu
ShuGuang Hospital